Cargando…

An Antitubulin Agent BCFMT Inhibits Proliferation of Cancer Cells and Induces Cell Death by Inhibiting Microtubule Dynamics

Using cell based screening assay, we identified a novel anti-tubulin agent (Z)-5-((5-(4-bromo-3-chlorophenyl)furan-2-yl)methylene)-2-thioxothiazolidin-4-one (BCFMT) that inhibited proliferation of human cervical carcinoma (HeLa) (IC(50), 7.2±1.8 µM), human breast adenocarcinoma (MCF-7) (IC(50), 10.0...

Descripción completa

Detalles Bibliográficos
Autores principales: Rai, Ankit, Surolia, Avadhesha, Panda, Dulal
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Public Library of Science 2012
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3432122/
https://www.ncbi.nlm.nih.gov/pubmed/22952952
http://dx.doi.org/10.1371/journal.pone.0044311
_version_ 1782242171429060608
author Rai, Ankit
Surolia, Avadhesha
Panda, Dulal
author_facet Rai, Ankit
Surolia, Avadhesha
Panda, Dulal
author_sort Rai, Ankit
collection PubMed
description Using cell based screening assay, we identified a novel anti-tubulin agent (Z)-5-((5-(4-bromo-3-chlorophenyl)furan-2-yl)methylene)-2-thioxothiazolidin-4-one (BCFMT) that inhibited proliferation of human cervical carcinoma (HeLa) (IC(50), 7.2±1.8 µM), human breast adenocarcinoma (MCF-7) (IC(50), 10.0±0.5 µM), highly metastatic breast adenocarcinoma (MDA-MB-231) (IC(50), 6.0±1 µM), cisplatin-resistant human ovarian carcinoma (A2780-cis) (IC(50), 5.8±0.3 µM) and multi-drug resistant mouse mammary tumor (EMT6/AR1) (IC(50), 6.5±1µM) cells. Using several complimentary strategies, BCFMT was found to inhibit cancer cell proliferation at G2/M phase of the cell cycle apparently by targeting microtubules. In addition, BCFMT strongly suppressed the dynamics of individual microtubules in live MCF-7 cells. At its half maximal proliferation inhibitory concentration (10 µM), BCFMT reduced the rates of growing and shortening phases of microtubules in MCF-7 cells by 37 and 40%, respectively. Further, it increased the time microtubules spent in the pause (neither growing nor shortening detectably) state by 135% and reduced the dynamicity (dimer exchange per unit time) of microtubules by 70%. In vitro, BCFMT bound to tubulin with a dissociation constant of 8.3±1.8 µM, inhibited tubulin assembly and suppressed GTPase activity of microtubules. BCFMT competitively inhibited the binding of BODIPY FL-vinblastine to tubulin with an inhibitory concentration (K(i)) of 5.2±1.5 µM suggesting that it binds to tubulin at the vinblastine site. In cultured cells, BCFMT-treatment depolymerized interphase microtubules, perturbed the spindle organization and accumulated checkpoint proteins (BubR1 and Mad2) at the kinetochores. BCFMT-treated MCF-7 cells showed enhanced nuclear accumulation of p53 and its downstream p21, which consequently activated apoptosis in these cells. The results suggested that BCFMT inhibits proliferation of several types of cancer cells including drug resistance cells by suppressing microtubule dynamics and indicated that the compound may have chemotherapeutic potential.
format Online
Article
Text
id pubmed-3432122
institution National Center for Biotechnology Information
language English
publishDate 2012
publisher Public Library of Science
record_format MEDLINE/PubMed
spelling pubmed-34321222012-09-05 An Antitubulin Agent BCFMT Inhibits Proliferation of Cancer Cells and Induces Cell Death by Inhibiting Microtubule Dynamics Rai, Ankit Surolia, Avadhesha Panda, Dulal PLoS One Research Article Using cell based screening assay, we identified a novel anti-tubulin agent (Z)-5-((5-(4-bromo-3-chlorophenyl)furan-2-yl)methylene)-2-thioxothiazolidin-4-one (BCFMT) that inhibited proliferation of human cervical carcinoma (HeLa) (IC(50), 7.2±1.8 µM), human breast adenocarcinoma (MCF-7) (IC(50), 10.0±0.5 µM), highly metastatic breast adenocarcinoma (MDA-MB-231) (IC(50), 6.0±1 µM), cisplatin-resistant human ovarian carcinoma (A2780-cis) (IC(50), 5.8±0.3 µM) and multi-drug resistant mouse mammary tumor (EMT6/AR1) (IC(50), 6.5±1µM) cells. Using several complimentary strategies, BCFMT was found to inhibit cancer cell proliferation at G2/M phase of the cell cycle apparently by targeting microtubules. In addition, BCFMT strongly suppressed the dynamics of individual microtubules in live MCF-7 cells. At its half maximal proliferation inhibitory concentration (10 µM), BCFMT reduced the rates of growing and shortening phases of microtubules in MCF-7 cells by 37 and 40%, respectively. Further, it increased the time microtubules spent in the pause (neither growing nor shortening detectably) state by 135% and reduced the dynamicity (dimer exchange per unit time) of microtubules by 70%. In vitro, BCFMT bound to tubulin with a dissociation constant of 8.3±1.8 µM, inhibited tubulin assembly and suppressed GTPase activity of microtubules. BCFMT competitively inhibited the binding of BODIPY FL-vinblastine to tubulin with an inhibitory concentration (K(i)) of 5.2±1.5 µM suggesting that it binds to tubulin at the vinblastine site. In cultured cells, BCFMT-treatment depolymerized interphase microtubules, perturbed the spindle organization and accumulated checkpoint proteins (BubR1 and Mad2) at the kinetochores. BCFMT-treated MCF-7 cells showed enhanced nuclear accumulation of p53 and its downstream p21, which consequently activated apoptosis in these cells. The results suggested that BCFMT inhibits proliferation of several types of cancer cells including drug resistance cells by suppressing microtubule dynamics and indicated that the compound may have chemotherapeutic potential. Public Library of Science 2012-08-31 /pmc/articles/PMC3432122/ /pubmed/22952952 http://dx.doi.org/10.1371/journal.pone.0044311 Text en © 2012 Rai et al http://creativecommons.org/licenses/by/4.0/ This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are properly credited.
spellingShingle Research Article
Rai, Ankit
Surolia, Avadhesha
Panda, Dulal
An Antitubulin Agent BCFMT Inhibits Proliferation of Cancer Cells and Induces Cell Death by Inhibiting Microtubule Dynamics
title An Antitubulin Agent BCFMT Inhibits Proliferation of Cancer Cells and Induces Cell Death by Inhibiting Microtubule Dynamics
title_full An Antitubulin Agent BCFMT Inhibits Proliferation of Cancer Cells and Induces Cell Death by Inhibiting Microtubule Dynamics
title_fullStr An Antitubulin Agent BCFMT Inhibits Proliferation of Cancer Cells and Induces Cell Death by Inhibiting Microtubule Dynamics
title_full_unstemmed An Antitubulin Agent BCFMT Inhibits Proliferation of Cancer Cells and Induces Cell Death by Inhibiting Microtubule Dynamics
title_short An Antitubulin Agent BCFMT Inhibits Proliferation of Cancer Cells and Induces Cell Death by Inhibiting Microtubule Dynamics
title_sort antitubulin agent bcfmt inhibits proliferation of cancer cells and induces cell death by inhibiting microtubule dynamics
topic Research Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3432122/
https://www.ncbi.nlm.nih.gov/pubmed/22952952
http://dx.doi.org/10.1371/journal.pone.0044311
work_keys_str_mv AT raiankit anantitubulinagentbcfmtinhibitsproliferationofcancercellsandinducescelldeathbyinhibitingmicrotubuledynamics
AT suroliaavadhesha anantitubulinagentbcfmtinhibitsproliferationofcancercellsandinducescelldeathbyinhibitingmicrotubuledynamics
AT pandadulal anantitubulinagentbcfmtinhibitsproliferationofcancercellsandinducescelldeathbyinhibitingmicrotubuledynamics
AT raiankit antitubulinagentbcfmtinhibitsproliferationofcancercellsandinducescelldeathbyinhibitingmicrotubuledynamics
AT suroliaavadhesha antitubulinagentbcfmtinhibitsproliferationofcancercellsandinducescelldeathbyinhibitingmicrotubuledynamics
AT pandadulal antitubulinagentbcfmtinhibitsproliferationofcancercellsandinducescelldeathbyinhibitingmicrotubuledynamics